RECURRENT SPONTANEOUS PNEUMOTHORAX UNDER NINTEDANIB TREATMENT IN INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SYSTEMIC SCLEROSIS

Senel A. S., Denizhan T., Kiziltepe M., Kokoglu E., Tutar N.

SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, cilt.40, sa.4, 2023 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 40 Sayı: 4
  • Basım Tarihi: 2023
  • Doi Numarası: 10.36141/svdld.v40i4.14716
  • Dergi Adı: SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Anahtar Kelimeler: nintedanib, spontaneus pnomotorax, systemic sclerosis
  • Erciyes Üniversitesi Adresli: Evet

Özet

. Interstitial lung disease (ILD) is a common complication that can develop during the course of systemic sclerosis (SSc). Nindetanib is an antifibrotic drug approved for the treatment of systemic sclerosis-associated interstitial lung disease. Although there is an insufficient data on the development of pneumothorax, the safety of Nintedanib treatment is also uncertain. We observed recurrent resistant pneumothorax under nintedanib treatment in a patient with systemic sclerosis-associated interstitial lung disease. Nintedanib use may increase the risk of developing refractory pneumothorax. Ssc patients who are started on nintedanib should be followed carefully for pneumothorax.